These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 23507358)
1. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Fatemi SH; Yousefi MK; Kneeland RE; Liesch SB; Folsom TD; Thuras PD Schizophr Res; 2013 May; 146(1-3):376-8. PubMed ID: 23507358 [No Abstract] [Full Text] [Related]
2. A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. Johnson TS J Am Acad Nurse Pract; 2010 Oct; 22(10):557-63. PubMed ID: 21040090 [TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191 [TBL] [Abstract][Full Text] [Related]
4. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Hong LE; Thaker GK; McMahon RP; Summerfelt A; Rachbeisel J; Fuller RL; Wonodi I; Buchanan RW; Myers C; Heishman SJ; Yang J; Nye A Arch Gen Psychiatry; 2011 Dec; 68(12):1195-206. PubMed ID: 21810630 [TBL] [Abstract][Full Text] [Related]
5. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788 [TBL] [Abstract][Full Text] [Related]
6. Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use. Ebbert JO Evid Based Med; 2013 Dec; 18(6):212-3. PubMed ID: 24030984 [No Abstract] [Full Text] [Related]
7. Varenicline in the management of smoking cessation: a single technology appraisal. Hind D; Tappenden P; Peters J; Kenjegalieva K Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684 [TBL] [Abstract][Full Text] [Related]
8. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Smith RC; Lindenmayer JP; Davis JM; Cornwell J; Noth K; Gupta S; Sershen H; Lajtha A Schizophr Res; 2009 May; 110(1-3):149-55. PubMed ID: 19251401 [TBL] [Abstract][Full Text] [Related]
9. Varenicline modulates spatial working memory deficits in smokers with schizophrenia. Wing VC; Wass CE; Bacher I; Rabin RA; George TP Schizophr Res; 2013 Sep; 149(1-3):190-1. PubMed ID: 23849883 [No Abstract] [Full Text] [Related]
11. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. Anghelescu I J Neuropsychiatry Clin Neurosci; 2009; 21(1):102-3. PubMed ID: 19359464 [No Abstract] [Full Text] [Related]
12. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Shim JC; Jung DU; Jung SS; Seo YS; Cho DM; Lee JH; Lee SW; Kong BG; Kang JW; Oh MK; Kim SD; McMahon RP; Kelly DL Neuropsychopharmacology; 2012 Feb; 37(3):660-8. PubMed ID: 22048460 [TBL] [Abstract][Full Text] [Related]
13. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Nides M; Glover ED; Reus VI; Christen AG; Make BJ; Billing CB; Williams KE Am J Health Behav; 2008; 32(6):664-75. PubMed ID: 18442345 [TBL] [Abstract][Full Text] [Related]
14. Varenicline efficacy and tolerability in a subject with schizophrenia. Fatemi SH Schizophr Res; 2008 Aug; 103(1-3):328-9. PubMed ID: 18572388 [No Abstract] [Full Text] [Related]
15. Varenicline for smoking cessation: definite promise, but no panacea. Klesges RC; Johnson KC; Somes G JAMA; 2006 Jul; 296(1):94-5. PubMed ID: 16820552 [No Abstract] [Full Text] [Related]
16. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. Meszaros ZS; Abdul-Malak Y; Dimmock JA; Wang D; Ajagbe TO; Batki SL J Clin Psychopharmacol; 2013 Apr; 33(2):243-7. PubMed ID: 23422399 [TBL] [Abstract][Full Text] [Related]
17. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Garza D; Murphy M; Tseng LJ; Riordan HJ; Chatterjee A Biol Psychiatry; 2011 Jun; 69(11):1075-82. PubMed ID: 21295286 [TBL] [Abstract][Full Text] [Related]
18. Smoking cessation in patients with chronic kidney disease. Raymond CB; Naylor HK CANNT J; 2010; 20(4):24-9; quiz 30-1. PubMed ID: 21319580 [No Abstract] [Full Text] [Related]
19. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. Cerimele JM; Durango A J Clin Psychiatry; 2012 Aug; 73(8):e1039-47. PubMed ID: 22967780 [TBL] [Abstract][Full Text] [Related]